The US Food and Drug Administration's Peripheral and Central NervousSystem Drugs Advisory Committee has voted to recommend approval of Orphan Medical's Xyrem (sodium oxybate) oral solution, a drug which contains the active ingredient gamma hydroxybutyrate and is notoriously abused as a date-rape drug, for reducing the incidence of cataplexy associated with narcolepsy.
The panel voted with a majority of six to three in support of approving the 9mg/day dose, and five to four for 6mg/day. It was also tied four to four (with one abstention) on the issue of safety, and voted eight to one that a risk-management plan is necessary for the safe use of Xyrem, as was recommended by the company. To minimize the abuse potential of the drug, Orphan has promised to limit the manufacturing to a single site, and also requires prescriptions be sent overnight to patients from a central pharmacy.
The company's chief executive, John Bullion, said that he was "encouraged by the outcome of the committee's deliberations, even though the voting was not unanimous. We will meet promptly with the FDA and feel confident we can address the clinical issues discussed by the committee."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze